Sign in
Not yet taking people in United StatesPhase 2

Tests quercetin supplement effects on small blood vessel function

Tests quercetin, a dietary supplement, against placebo in adults with microvascular dysfunction.

Key facts

Who runs it
Medical College of Wisconsin
Where
Wauwatosa, United StatesSee the site
Trial code
Registry title
Palmitic Acid and Human Microvascular Function
Status
Not yet recruiting
Phase
Phase 2
People taking part
40 people, planned
Started
Jul 2026
Expected to end
Dec 2030
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Quercetin (dietary supplement)
  • Placebo
Record updated
29 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 40 with obesity (BMI over 30) who speak English. It studies how the supplement Quercetin affects blood vessel function.

Age
18 to 40 years
Sex
All sexes can join.
Disease stage
Obesity, with a BMI over 30.

Main reasons for not taking part

  • BMI over 60
  • Resting blood pressure of 180 mmHg or more (top number) or 110 mmHg or more (bottom number)
  • Pregnancy or breastfeeding
  • Past heart attack
  • More than 1 risk factor for coronary artery disease (active smoker, diabetes, heart failure, high blood fats, high blood pressure)

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Obesity (BMI>30)
  • Aged 18-40 years
  • English Speaking

Who cannot take part

  • Prior history of myocardial infarction
  • Diagnosis of more than 1 risk factor for coronary artery disease (active smoker, diabetes mellitus- type 1 or 2, congestive heart failure, hyperlipidemia, hypertension)
  • BMI>60
  • Resting SBP ≥180 mmHg or DBP ≥ 110mmHg
  • Pregnancy or breastfeeding
  • Active mouth sores that affect the buccal mucosa

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 40 years old?

Where in United States

  • Froedtert HospitalWauwatosa, United StatesContact: Julia VogtNot yet recruiting

About the trial

What the trial wants to find out

The goal of this study is to learn how a supplement Quercetin can affect microvascular function.

Read full original descriptionShow less

Participants will:

* give two blood draws of 5 mL each * have a camera placed under the tongue to take pictures of blood vessels * have 2 laser Doppler microdialysis catheters placed on the forearm to monitor blood vessels before and after local drug infusion

Researchers will compare blood vessel function of those who take estrogen supplements to those who do not.

The 2 groups in the trial

  • Use of oral quercetin to improve human microvascular functionTreatment being tested

    Quercetin is a non-FDA approved, over-the-counter supplement that has been shown to improve oxidative capacity in blood vessels.

    Treatment: Quercetin (dietary supplement)

  • PlaceboPlacebo, for comparison

    A placebo will be administered for 30 days followed by assessment of the subject's microvascular function.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Use of Quercetin to Increase Resiliency to Palmitic Acid in the Human Microvasculature
Plain-language title
Tests quercetin supplement effects on small blood vessel functionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06683534, who can take part
Record updated
29 April 2026